Prevention and treatment of glucocorticoid-induced osteoporosis in 2005

Joint Bone Spine - Tập 72 - Trang 461-465 - 2005
Philippe Orcel1
1Fédération de rhumatologie, centre Viggo-Petersen, hôpital Lariboisière, 2, rue Ambroise-Paré, 75475 Paris cedex 10, France

Tài liệu tham khảo

Orcel, 2001, Ostéoporose cortisonique, Rev. Rhum., 68, 678, 10.1016/S1169-8330(01)00181-8

Di Somma, 2002, Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study, Clin. Endocrinol. (Oxf.), 56, 302

Roux, 2003, Prévention et traitement de l’ostéoporose cortisonique, Rev Med Int, 24, 384, 10.1016/S0248-8663(03)00105-X

Walsh, 1996, Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study, BMJ, 313, 344, 10.1136/bmj.313.7053.344

van Staa, 2000, Use of oral corticosteroids in the United Kingdom, QJM, 93, 105, 10.1093/qjmed/93.2.105

Peat, 1995, Steroid induced osteoporosis: an opportunity for prevention?, Ann. Rheum. Dis., 54, 66, 10.1136/ard.54.1.66

Buckley, 1998, Variations in physicians’ judgments about corticosteroid induced osteoporosis by physician specialty, J. Rheumatol., 25, 2195

Curtis, 2004, Screening and treatment of glucocorticoid induced osteoporosis among 6517 adults, J Bone Miner Res, 19, S30

Soucy, 2000, A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists, J. Rheumatol., 27, 1506

van Staa, 2000, Use of oral corticosteroids and risk of fractures, J. Bone Miner. Res., 15, 993, 10.1359/jbmr.2000.15.6.993

van Staa, 2000, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, Rheumatol., 39, 1383, 10.1093/rheumatology/39.12.1383

van Staa, 2003, Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy, Arthritis Rheum., 48, 3224, 10.1002/art.11283

Eastell, 1998, A UK consensus group on management of glucocorticoid-induced osteoporosis: an update, J. Intern. Med., 244, 271, 10.1046/j.1365-2796.1998.00408.x

Van Staa, 2005, A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids, Q. J. Med., 98, 191, 10.1093/qjmed/hci029

Hall, 1994, Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids, Arthritis Rheum., 37, 1499, 10.1002/art.1780371014

Buckley, 1996, Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial, Ann. Intern. Med., 125, 961, 10.7326/0003-4819-125-12-199612150-00004

Homik, 2000, Calcium and vitamin D for corticosteroid-induced osteoporosis, Cochrane Database Syst Rev, 2

Chavassieux, 2000, Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies, J. Bone Miner. Res., 15, 754, 10.1359/jbmr.2000.15.4.754

Plotkin, 1999, Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin, J. Clin. Invest., 104, 1363, 10.1172/JCI6800

Adachi, 1997, Intermittent etidronate to prevent corticosteroid-induced osteoporosis, N. Engl. J. Med., 337, 382, 10.1056/NEJM199708073370603

Roux, 1998, Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss, J. Clin. Endocrinol. Metab., 83, 1128, 10.1210/jc.83.4.1128

Adachi, 2000, A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss, J. Rheumatol., 27, 2424

Saag, 1999, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis, N. Engl. J. Med., 339, 292, 10.1056/NEJM199807303390502

Adachi, 2001, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial, Arthritis Rheum., 44, 202, 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W

Cohen, 1999, Risedronate therapy prevents corticosteroid-induced bone loss: a 12-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Arthritis Rheum., 42, 2309, 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K

Reid, 2000, Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study, J. Bone Miner. Res., 15, 1006, 10.1359/jbmr.2000.15.6.1006

Eastell, 2000, Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients, Osteoporos. Int., 11, 331, 10.1007/s001980070122

Wallach, 2000, Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy, Calcif. Tissue Int., 67, 277, 10.1007/s002230001146

Boutsen, 2001, Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone, J. Bone Miner. Res., 16, 104, 10.1359/jbmr.2001.16.1.104

Ringe, 2003, Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study, Osteoporos. Int., 14, 801, 10.1007/s00198-003-1425-0

Homik, 1999, A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis, J. Rheumatol., 26, 1148

Homik, 2000, Bisphosphonates for steroid induced osteoporosis, Cochrane Database Syst Rev, 2

1996, Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis, Arthritis Rheum., 39, 1791, 10.1002/art.1780391104

Adachi, 2000, Management of corticosteroid-induced osteoporosis, Semin. Arthritis Rheum., 29, 228, 10.1016/S0049-0172(00)80011-6

AFSSAPS. Traitement medicamenteux de l’ostéoporose cortisonique. Recommandation de Bonne Pratique 2003. http://agmed.sante.gouv.fr/htm/5/rbp/indrbp.htm.

ANAES. L’ostéoporose chez les femmes ménopausées et chez les sujets traites par corticoïdes: méthodes diagnostiques et indications. Recommandations et références professionnelles 2001. http://www.has-sante.fr/anaes/anaesparametrage.nsf.

Jilka, 1999, Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone, J. Clin. Invest., 104, 439, 10.1172/JCI6610

Lane, 1998, Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial, J. Clin. Invest., 102, 1627, 10.1172/JCI3914

Manolagas, 1999, New developments in the pathogenesis and treatment of steroid-induced osteoporosis, J. Bone Miner. Res., 14, 1061, 10.1359/jbmr.1999.14.7.1061

Thông tin
Thông tin xuất bản

Joint Bone Spine

Tập 72

461-465

Thông tin tác giả